Sanford Health participated in a national study that examined the effect of genotype-guided treatment on cardiovascular outcomes after a heart procedure known as percutaneous coronary intervention, or PCI, in which a metallic stent is inserted into a heart artery to treat a blockage.
Researchers discovered about 30% of patients have a genetic deficiency that impairs their ability to activate Plavix (clopidogrel), increasing their risk for adverse cardiovascular events such as strokes, heart attacks and death.
Patients with the genetic deficiency were given a different, more effective medication.
On average during the study, a patient’s genetic information was available in about one day, and an alternative medication was provided within a similar time.
Patients with the genetic deficiency who received an alternative medication were less likely to have a major adverse cardiovascular event compared with those who received clopidogrel during the follow-up period of up to a year, researchers found.
One simple solution
One simple genetic test can significantly reduce the of risk heart attacks a for heart stent patients. The genetic testing allows physicians to pinpoint the best anti-clotting medication for each patient.
Having timely access to a patient’s genetic information can be particularly helpful as physicians work to prescribe the most appropriate medicine.
Call (605) 312-2278 to learn if this genetic test is right for you.